November 9-10, 2016: Meeting Materials FDA Generated
Waiver: Randall T. Hayden, M.D.
Acknowledgment: Randall T. Hayden, M.D.
Waiver: Michael G. Ison, M.D., M.S.
Acknowledgment: Michael G. Ison, M.D., M.S.
Waiver: Joanna M. Schaenman, M.D., Ph.D.
Acknowledgment: Joanna M. Schaenman, M.D., Ph.D.
Agenda: Nov. 9, 2016
Roster: Nov. 9, 2016
Panel Questions: Nov. 9, 2016
FDA Executive Summary: Nov. 9, 2016
Presentation - Device Reclassification: Nov. 9, 2016
Presentation - Discussion and Recommendations for the Classification of Quantitative Viral Load Assays for Transplant-associated Opportunistic Viral Infections: Nov. 9, 2016
Presentation - Background of CMV Regulatory Path and Intended Use: Nov. 9, 2016
Presentation - FDA Perspective on CMV Viral Load Assay Reclassification: Nov. 9, 2016
Presentation - EBV and BK Viruses: Nov., 9, 2016
Agenda: Nov. 10, 2016
Roster: Nov. 10, 2016
FDA Executive Summary: Nov. 10, 2016
FDA Executive Summary - Errata: Nov. 10, 2016
Presentation - Clinical Considerations for Procalcitonin-Guided Evaluation and Management of Lower Respiratory Tract Infections and Sepsis: Nov. 10, 2016
Presentation - Procalcitonin for the Evaluation and Antibiotic Management of Suspected Lower Respiratory Tract Infections and Sepsis: Nov. 10, 2016
Presentation - Statistical Considerations for Procalcitonin-Guided Evaluation and Management of Lower Respiratory Tract Infections and Sepsis: Nov. 10, 2016
24 Hour Summary: Nov. 9, 2016
24 Hour Summary: Nov. 10, 2016
Transcript: Nov. 9, 2016
Transcript: Nov. 10, 2016
November 9-10, 2016: Meeting Materials Non-FDA Generated
August 16, 2016: Meeting Materials FDA Generated
August 16, 2016: Meeting Materials Non-FDA Generated
Content current as of:
03/23/2018
Back to Top